CPSC Proposes to Require Child-Resistant Packaging for Certain OTC Drugs
The Consumer Product Safety Commission is proposing a rule to require child-resistant (CR) packaging for any over-the-counter or prescription product containing the equivalent of 0.08 milligrams or more of an imidazoline in a single package. Imidazolines are a class of…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
drugs that includes tetrahydrozoline, naphazoline, oxymetazoline, and xylometazoline, which are vasoconstrictors indicated for nasal congestion and/or ophthalmic irritation. CPSC states products containing imidazolines can cause serious adverse reactions, such as central nervous system depression, decreased heart rate, and depressed ventilation in children treated with these drugs or who accidentally ingest them. CPSC preliminarily finds that special packaging is required to protect children under 5 years old from serious personal injury or illness due to handling, using, or ingesting such a substance. Comments are due on or about April 16, 2012.